Efficacy of Dabigatran Etexilate in the Treatment of Atrial Fibrillation Complicated with Acute Coronary Syndrome and its Effect on the Prognosis of Patients
Objective To observe the efficacy of dabigatran etexilate in the treatment of atrial fibrillation complicated with acute coronary syndrome and its effect on the prognosis of patients.Methods A total of 62 patients with atrial fibrillation complicated with acute coronary syndrome who were treated in our hospital from January 2021 to March 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 31 patients in each group.The control group was treated with conventional therapy,and the observation group was treated with dabigatran etexilate on the basis of the control group.The clinical efficacy,complication rate,coagulation function indexes[prothrombin time(PT),activated partial thromboplastin time(APTT),plasma thrombin time(TT)]and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.55％,which was higher than 80.65％in the control group(P＜0.05).The incidence of complications in the observation group was 9.68％,which was lower than 22.58％in the control group(P＜0.05).After treatment,PT,APTT and TT in the two groups were higher than those before treatment,and those in the observation group were higher than the control group(P＜0.05).The incidence of adverse reactions in the observation group was 6.45％,which was compared with 9.68％in the control group,the difference was not statistically significant(P＞0.05).Conclusion Dabigatran etexilate has a definite clinical effect in the treatment of atrial fibrillation complicated with acute coronary syndrome.It can improve the prognosis and coagulation function indexes of patients,effectively reduce the incidence of complications,and does not increase the incidence of adverse reactions.Thus,it can be used as an effective drug for clinical treatment of atrial fibrillation complicated with acute coronary syndrome.
Dabigatran etexilateAtrial fibrillationAcute coronary syndromeBlood coagulation function
万方数据
维普
